FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics, namely, to treating interstitial pulmonary disease (ILD). Disclosed is the use of benzisoselenazole derivatives of formula (I-1) for preparing drugs for treating interstitial lung disease. In general formula (I-1), R is selected from hydrogen, cyano, hydroxyl, halogen; p is integer from 0 to 4; L is selected from -(CH2)n-, -(CH2)n-O-(CH2)n-, -(CH2)n-S-S-(CH2)m-, -phenyl-(CH2)n-S(O)2- and -(CH2)n-S(O)2-phenyl-, where n is integer from 0 to 12, m is integer from 0 to 12.
EFFECT: use of the invention enables effective treatment of interstitial lung disease caused by coronavirus.
3 cl, 15 dwg, 25 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING INFLAMMATORY DISEASES | 2019 |
|
RU2827865C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL PREPARATIONS | 2013 |
|
RU2701156C2 |
| FAP INHIBITOR | 2019 |
|
RU2797409C2 |
| BUPRENORPHINE ANALOGUES | 2009 |
|
RU2520222C2 |
| COMBINATION OF MCL-1 INHIBITOR AND TAXANE COMPOUND, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2763544C2 |
| METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | 2017 |
|
RU2765737C2 |
| PRODUCT COMPRISING AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF NO-SYNTHASE IN COMBINATION WITH AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF PHOSPHOLIPASE A | 2000 |
|
RU2256465C2 |
| NEW DRUG FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS AND FIBROSIS | 2017 |
|
RU2762280C2 |
| METHOD OF TREATING HEPATIC FIBROSES | 2017 |
|
RU2740902C2 |
